PMID: 8605698Mar 1, 1996Paper

Indirect recognition of donor MHC Class II antigens in human transplantation

Clinical Immunology and Immunopathology
Z LiuN Suciu-Foca

Abstract

To investigate the role of the indirect pathway of recognition in human allograft rejection, we have mapped the dominant T cell determinant of the HLA-DRbeta1*0101 molecule presented by the DRbeta1*1101 antigen. A synthetic peptide (pp 22-35) corresponding to the sequence of the dominant peptide determinant was used for testing the frequency of in vivo activated T cells in the graft and in the periphery. DRbeta1*1101-positive patients carrying a heart allograft mismatched for the HLA-DR1 antigen showed no reactivity to pp 22-35 during quiescence. However, interleukin-2-responsive T cells, which were pp 22-35 specific, were found in the circulation prior to and at the time of acute and chronic rejection. The response of in vivo and in vitro activated T cells was inhibited at high concentrations of peptide 22-35. This data suggests that indirect recognition plays an important role in allograft rejection and that it can be abolished by high zone tolerance induction.

Citations

Feb 1, 1997·Transplantation Proceedings·Z LiuN Suciu-Foca
Sep 2, 1998·Transplantation Proceedings·N Suciu-FocaR Cortesini
Aug 17, 2002·Current Opinion in Immunology·Sita Gourishankar, Philip F Halloran
Sep 12, 2003·Transplant Immunology·Nicole Suciu-FocaRaffaello Cortesini
Jan 18, 2003·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Kim C LuT Mohanakumar
Oct 27, 1997·Transplantation·S TuguleaN Suciu-Foca
Jul 11, 2006·Transplantation·Raffaello Cortesini, Nicole Suciu-Foca
Oct 31, 1998·Immunological Reviews·N Suciu-FocaR Cortesini
Feb 7, 1998·The Journal of Clinical Investigation·R CiubotariuN Suciu-Foca
Sep 12, 2003·Transplant Immunology·John S ManavalanNicole Suciu-Foca
Jul 10, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·S I ReznikT Mohanakumar
May 19, 2009·Human Immunology·Persis P WadiaAnat R Tambur
Oct 20, 2005·Clinical and Experimental Immunology·J A BradleyG Pettigrew
Jun 5, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Rachel E StanfordMarlene L Rose
Sep 24, 2004·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Marlene L Rose
Sep 24, 2004·Transplant Immunology·Nicole Suciu-Foca CortesiniRaffaello Cortesini
Mar 18, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·V CoelhoJ Kalil
Dec 1, 2001·Clinical Immunology : the Official Journal of the Clinical Immunology Society·M Spadafora-FerreiraV Coelho
Jun 2, 2016·Journal of Translational Medicine·Giovanni StalloneGiuseppe Grandaliano
Feb 15, 2001·American Journal of Orthodontics and Dentofacial Orthopedics : Official Publication of the American Association of Orthodontists, Its Constituent Societies, and the American Board of Orthodontics·S K Carlson, E Johnson
Jul 27, 2007·Journal of Leukocyte Biology·Pascale HubertPhilippe Delvenne
Feb 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Toru HiguchiThalachallour Mohanakumar
Oct 25, 2001·Journal of the American Society of Nephrology : JASN·Karl L WomerMohamed H Sayegh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.